A federal appeals court said the US government was right to appeal Illumina‘s acquired cancer evaluate maker Grail, but still sent the case back to the Federal Trade Commission for reconsideration.

A three-evaluate panel found the deal anticompetitive, but said the FTC erred in how it viewed Illumina’s proposed cure. The judges ordered the FTC to reconsider its opinion on the troubled deal, which had already been ordered by the European Commission Illumina for recreation.

Copyright ©2023 year Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Source link